Kyverna Therapeutics
Market cap $297M 63.2M shares (10-Q, Nov 6, 2026) × $4.70 close Nov 17, 2026
Most recent annual filing: 2026-03-26
- Kyverna Pipeline RA readout2026Kyverna Pipeline RA readout, 2026, notable
- Miv-cel (KYV-101) Rheumatoid Arthritis Ph22026Miv-cel (KYV-101) Rheumatoid Arthritis Ph2, 2026, notable
- Miv-cel Ph1 readout2026Miv-cel Ph1 readout, 2026, notable
- Oxford Term A Loan corporate4Q 2026Oxford Term A Loan corporate, 4Q 2026, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
mivocabtagene autoleucel
miv-cel · KYV-101 · KYSA-6mivocabtagene autoleucel
miv-cel · KYV-101KYV-201
- Undisclosed indication
Technology platforms
Ingenui-T · ElevateBio BaseCamp
Proprietary whole blood rapid manufacturing process for CAR T-cell therapies, designed to eliminate apheresis starting material and reduce manufacturing turnaround time; focus on autologous CD19 CAR T for autoimmune diseases
Targets: CD19
Discontinued (1)
- KYV-102 — undisclosed · strategic deprioritization to focus on late-stage neurologic indications with miv-cel
Capital (as filed)
- Cash
- $31.8M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $139M Sep 30, 2026
- Operating cash flow
- −$35.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $171M cash, runway 2028 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (9)
- 2026-11-13 UPDATE: Kyverna Therapeutics (KYTX) - The BLA Is In, The Savior Is Shelved 🔒 Paid
- 2026-09-24 UPDATE: Kyverna Therapeutics (KYTX) - The Durability Check Clears 🔒 Paid
- 2026-09-02 UPDATE: Kyverna Therapeutics (KYTX) - A Company Doesn’t Issue This Press Release on a Quiet Day 🔒 Paid
- 2026-08-12 UPDATE: Kyverna Therapeutics (KYTX) - Three RMATs and the First ATM Draw 🔒 Paid
- 2026-07-28 UPDATE: Kyverna Therapeutics (KYTX) - The Factory Signs a Commercial Lease 🔒 Paid
- 2026-06-03 UPDATE: Kyverna Therapeutics (KYTX) - The RA Receipts Land, the Stock Doesn’t Care 🔒 Paid
- 2026-05-12 UPDATE: Kyverna Therapeutics (KYTX) - The BLA Clock Starts 🔒 Paid
- 2026-04-27 UPDATE: Kyverna Therapeutics (KYTX) - The SPS Receipts Land, And They’re Better Than the Topline 🔒 Paid
- 2026-04-22 Kyverna Therapeutics (KYTX) - Scientific Deep Dive for Miv-Cel and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (9 calls)
Every verdict Biotech Distilled has published on Kyverna Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-04-22 Watch Kyverna Therapeutics (KYTX) - Scientific Deep Dive for Miv-Cel and Pipeline Products The science and SPS data are compelling but the author wants clarity on FDA's stance on the BLA before taking a position.
- 2026-04-27 Speculative buy speculative UPDATE: Kyverna Therapeutics (KYTX) - The SPS Receipts Land, And They're Better Than the Topline The KYSA-8 primary analysis retired clinical risk in SPS with a clean registration package, justifying an upgrade from Watch to Speculative Buy, though commercial and manufacturing risks remain.
- 2026-05-12 Buy core UPDATE: Kyverna Therapeutics (KYTX) - The BLA Clock Starts FDA alignment on the single-arm KYSA-8 pivotal removes the largest regulatory tail risk, shifting the story from clinical-stage hope to commercial-stage prep.
- 2026-06-03 Buy core UPDATE: Kyverna Therapeutics (KYTX) - The RA Receipts Land, the Stock Doesn't Care EULAR COMPARE data showing 66.6% ACR70 in refractory RA validates the deep-clean mechanism beyond SPS, and the disconnect between positive reads and the 23.6% stock decline looks like a sentiment/ATM overhang rather than a fundamental problem.
- 2026-07-28 Buy core UPDATE: Kyverna Therapeutics (KYTX) - The Factory Signs a Commercial Lease The five-year ElevateBio commercial supply agreement with a >98% manufacturing success rate de-risks the CMC leg of the SPS BLA, stepping down the 'High' manufacturing risk grade for the SPS launch specifically.
- 2026-08-12 Buy core UPDATE: Kyverna Therapeutics (KYTX) - Three RMATs and the First ATM Draw A third RMAT designation in naSPMS and a filed CMC module extend regulatory de-risking, though the balance sheet has shifted from 'fully funded' to 'funded via levers' and the ATM has now been tapped.
- 2026-09-02 Buy core UPDATE: Kyverna Therapeutics (KYTX) - A Company Doesn't Issue This Press Release on a Quiet Day Kyverna's unsolicited safety reaffirmation (>100 patients, zero high-grade CRS/ICANS, no program pauses) is consistent with the construct-level differentiation argued since March, and nothing in the statement contradicts the five consecutive positive reads since May.
- 2026-09-24 Buy core UPDATE: Kyverna Therapeutics (KYTX) - The Durability Check Clears One-year KYSA-8 data confirm durable SPS benefit (49% T25FW improvement, p<0.0001, 95% of responders sustained) with no new acute safety signals, though the '100% off immunotherapy' headline slipped to 92% and the stock is down 16% on sector sentiment.
- 2026-11-13 Hold UPDATE: Kyverna Therapeutics (KYTX) - The BLA Is In, The Savior Is Shelved The SPS BLA was filed on time with strong durability data, but shelving KYV-102 shrinks the platform thesis to neurology only, the IPO lawsuit survived, and the ATM is being drawn at progressively lower prices, making the risk/reward now dependent almost entirely on FDA acceptance.
- Long call · opened Apr 27, 2026 at $8.99 · -47.7% vs XBI +9.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“In August 2026, the FDA granted RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis, or naSPMS, which provides the opportunity for increased FDA engagement and eligibility for priority and rolling reviews, as well as accelerated approval pathways.”
matched to Miv-cel (KYV-101) · regulatory submission / matched to Miv-cel (KYV-101) Lupus Nephritis (KYSA-1/KYSA-3) · readout other
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (37)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 4, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseKyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1→ BD updateKyverna crossed the BLA finish line for miv-cel in SPS — the milestone I've been tracking since March — but buried in the same press release is a decision to kill KYV-102, the rapid manufacturing program I called the "commercial unlock" for broad indications. The gate is open; the key to what's behind it just got thrown away.
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 9, 2026ReleaseKyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology
- Nov 5, 2026ReleaseKyverna Therapeutics to Present at the Jefferies London Healthcare Conference
- Oct 23, 2026ReleaseKyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026BD extracted 1 program update from this document → KYTX pipeline
- Oct 21, 2026ReleaseKyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS TorontoBD extracted 1 program update from this document → KYTX pipeline
- Oct 7, 2026ReleaseKyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026BD extracted 2 program updates from this document → KYTX pipeline
- Sep 24, 2026ReleaseKyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis→ BD updateSummary on the 8-K
- Sep 24, 20268-KCurrent report: Reg FD disclosure · EX-99.1→ BD updateKYSA-8's one-year SPS data just deepened — T25FW improvement went from 46% at Week 16 to 49% at Month 12, with 95% of responders holding their gains and the BLA still on track for Q4. The stock is down 16% on the day despite what looks like a clean durability receipt.BD extracted 1 program update from this document → KYTX pipeline
- Sep 1, 2026ReleaseCompany Statement on Miv-cel's Favorable Safety Profile→ BD updateKyverna broke silence today with a reactive safety statement defending miv-cel's tolerability profile against unnamed "third-party reports" — the first crack in the CAR-T safety narrative to surface during the rolling BLA window, and exactly the kind of event the prior writeup's bear case warned could materialize.BD extracted 2 program updates from this document → KYTX pipeline
- Aug 11, 2026ReleaseKyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
- Aug 11, 20268-KCurrent report: results of operations · EX-99.1
- Aug 11, 202610-QQuarterly report
- Jul 27, 2026ReleaseKyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
- Jul 27, 20268-KCurrent report: material agreement, Reg FD disclosure · EX-99.1
- Jul 9, 20268-KCurrent report: material agreement
- Jun 22, 2026ReleaseKyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
- Jun 3, 2026ReleaseKyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid ArthritisBD extracted 1 program update from this document → KYTX pipeline
- Jun 2, 20268-KCurrent report: shareholder vote
- May 18, 2026ReleaseKyverna Therapeutics Names Greg Martini as Chief Financial Officer
- May 18, 20268-KCurrent report: officer / director change, other events · EX-99.1
- May 14, 2026ReleaseKyverna Therapeutics to Present at Upcoming Investor Conferences
- May 12, 2026ReleaseKyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- May 4, 2026ReleaseKyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
- May 4, 20268-KCurrent report: other events · EX-99.1
- Apr 22, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Apr 22, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Apr 20, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Apr 13, 2026DEFA14AProxy soliciting material
- Apr 13, 2026DEF 14AProxy statement
- Apr 2, 2026424B5Prospectus supplement (offering)
- Mar 26, 2026S-3Shelf registration
- Mar 26, 20268-KCurrent report: results of operations · EX-99.1
- Mar 26, 202610-KAnnual report
9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Oct 19, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jul 29, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 13, 2026ARSAnnual report to shareholders
- Apr 2, 2026EFFECTRegistration effective
- Mar 31, 2026CORRESPCORRESP
- Mar 30, 2026UPLOADUPLOAD
- Mar 26, 2026S-8Employee plan registration